logo
Children's National Hospital in DC to end gender transition medical interventions

Children's National Hospital in DC to end gender transition medical interventions

Fox News2 days ago
Children's National Hospital in Washington, D.C., has announced that it will no longer provide gender transition-related medical interventions.
The web page for the hospital's "Gender Development Program" displays a message for existing and new patients announcing the change, which will go into effect Aug. 30.
"In light of escalating legal and regulatory risks to Children's National, our providers, and the families we serve, we will be discontinuing the prescription of gender-affirming medications," the message says. "Mental health and other support services for LGBT patients remain available. You are always welcome at Children's National for your other medical needs."
"We know this change will have a significant impact on affected patients, families and staff. Our care teams are working directly with families of current patients to support them," it adds, urging people with questions to contact the hospital directly.
The announcement comes after the Justice Department on July 9 sent more than 20 subpoenas to doctors and clinics involved in performing transgender medical procedures on children.
The Trump administration said DOJ investigations include healthcare fraud, false statements and more.
"Medical professionals and organizations that mutilated children in the service of a warped ideology will be held accountable by this Department of Justice," Attorney General Pamela Bondi said in a statement at the time.
It was not immediately clear if Children's National received a subpoena.
In late January, President Donald Trump signed an executive order titled, "Protecting Children From Chemical and Surgical Mutilation," which directed federal agencies to slash Medicare, Medicaid and other federal funding from providers offering so-called "gender‑affirming care" to patients under the age of 19. A federal judge in February issued a nationwide temporary restraining order, blocking the order while litigation filed by LGBTQ advocacy groups proceeds.
Children's National Hospital was among several hospitals that paused prescriptions, refills and medication to minors as a result of Trump's order but later resumed such transgender services after the court intervened, according to The Washington Post.
Since Friday's announcement that the hospital would stop providing gender-transition services to children on Aug. 30, the Post obtained a message sent out to impacted families saying Children's National teams "are available to assist you as you move forward" but will no longer evaluate patients for medication or monitor medications through labs such as blood work.
According to Trump's executive order, "Across the country today, medical professionals are maiming and sterilizing a growing number of impressionable children under the radical and false claim that adults can change a child's sex through a series of irreversible medical interventions. This dangerous trend will be a stain on our Nation's history, and it must end."
The order claims, "countless children soon regret that they have been mutilated and begin to grasp the horrifying tragedy that they will never be able to conceive children of their own or nurture their children through breastfeeding," and, moreover, "these vulnerable youths' medical bills may rise throughout their lifetimes, as they are often trapped with lifelong medical complications, a losing war with their own bodies, and, tragically, sterilization."
It adds that the U.S. "will not fund, sponsor, promote, assist, or support the so-called 'transition' of a child from one sex to another, and it will rigorously enforce all laws that prohibit or limit these destructive and life-altering procedures."
Ben Takai, the board president of Metro DC PFLAG, which is involved in the lawsuit challenging Trump's order, told the Post the change at Children's National was sad, adding that "there are many ways to bully minority populations."
Children's National asserts on its gender development program's web page that "some young people feel, sense or know they are a gender different than the one they were assumed at birth."
"They may live and dress in ways typical of another gender (gender non-conformity), and some may experience the need to live and be affirmed as this gender in some or all settings," the hospital says. "This can be an urgent need, or for others, there may be experimentation and exploration. There are also some young people who show gender non-conformity in their everyday behaviors, but may not yet have the self-advocacy skills to discuss their gender identity and their gender-related needs."
The hospital website says parental consent is required to provide "gender-affirming medical care" to a minor in the District of Columbia. The hospital also says it does not provide "gender-affirming surgery" for anyone under the age of 18 and does not provide hormone therapy to children before puberty begins.
The U.S. Department of Health and Human Services in May released a report framing gender transition treatments for minors as risky and insufficiently studied. To treat pediatric gender dysphoria, it recommends replacing most medical interventions with "exploratory therapy." The report says that the "gender-affirming" model of care "includes irreversible endocrine and surgical interventions on minors with no physical pathology."
"These interventions carry risk of significant harms including infertility/sterility, sexual dysfunction, impaired bone density accrual, adverse cognitive impacts, cardiovascular disease and metabolic disorders, psychiatric disorders, surgical complications, and regret," according to HHS. "Meanwhile, systematic reviews of the evidence have revealed deep uncertainty about the purported benefits of these interventions."
The report notes that the United Kingdom in December 2024 indefinitely banned puberty blockers for children with gender dysphoria. Meanwhile, amid pressure from the Trump administration, the Center for Transyouth Health and Development at Children's Hospital Los Angeles, considered the largest public provider of "gender-affirming care" for children and teens in the U.S., announced earlier this month that it was closing by July 22.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

Yahoo

time8 minutes ago

  • Yahoo

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates
U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

Yahoo

time8 minutes ago

  • Yahoo

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

HOUSTON, July 23, 2025--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three months and six months ended June 30, 2025, on Wednesday, August 6, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 7, 2025. Conference Call Date: Thursday, August 7, 2025 Time: 10:30 am Eastern / 9:30 am Central Dial-In Number: (800) 343-4136 Primary or (203) 518-9843 Alternate Conference ID: USPHQ225 (In order to join this conference call,you will be required to provide the Conference ID listed above) To participate, please call in 15 minutes prior to start time. To listen to the live call, please go to and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025 at USPH's website. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 768 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release. View source version on Contacts U.S. Physical Therapy, Hendrickson, Chief Financial OfficerEmail: Chendrickson@ Chris Reading, Chief Executive Officer(713) 297-7000 Three Part AdvisorsJoe Noyons(817) 778-8424

The president vows to slash medication cost to an unachievable degree.
The president vows to slash medication cost to an unachievable degree.

Yahoo

time8 minutes ago

  • Yahoo

The president vows to slash medication cost to an unachievable degree.

President Donald Trump has promised to reduce American drug prices by mathematically impossible figures of up to '1400 percent.' Speaking during a White House event attended by Republican members of Congress and his Cabinet, Trump said he would tackle the long-running issue of high medication costs in the U.S. But Trump did not set any achievable targets for that aim, instead outlining a range of percentages which would yield negative prices, meaning drug companies would have to pay people to take their medications.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store